Chugai Transfers the Manufacturing and Marketing Rights of VESANOID® to Fuji Pharma

On August 31, 2016 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) and Fuji Pharma Co., Ltd. (TOKYO: 4554) reported that they agreed to transfer the rights to manufacture and market VESANOID (generic name: tretinoin, brand name: VESANOID capsule 10mg) in Japan for the indication of acute promyelocytic leukemia (APL), from Chugai to Fuji Pharma effective on November 1, 2016.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

VESANOID is an orally available vitamin A derivative for the treatment of APL developed by Roche. In Japan, VESANOID was designated as orphan drug by the Minister of Health, Labour and Welfare, in 1993 and has been on the market since March 1995.

In order to ensure the constant supply of VESANOID, Chugai continues to distribute the product in the interim. Once all Chugai labeled products have been sold to the market, the distribution of Fuji Pharma labeled products will be implemented.

Chugai and Fuji Pharma will cooperate to accomplish a smooth transition of manufacturing and marketing of VESANOID, together by delivering products and their information meeting medical needs, as well as promoting the appropriate use of VESANOID.

In April 2016, the business transfer agreement for VESANOID to manufacture and market in Japan was concluded among Cheplapharm Arzneimittel GmbH, Roche and Chugai. Cheplapharm acquired the manufacturing and marketing rights of VESANOID in Japan and licensed out those rights to Fuji Pharma.